Efficacy of pegylated interferon-atreatment for 24 months in chronic delta hepatitis and predictors of response

Antiviral Therapy

Volumn 18, Issue 4, 2013, Pages 561-566

  Karaca, Cetin ^a   Soyer, Ozlem M ^a   Baran, Bulent ^a   Ormeci, Asli C ^a   Gokturk, Suut ^a   Aydin, Esra ^a   Evirgen, Sami ^a   Akyuz, Filiz ^a   Demir, Kadir ^a   Besisik, Fatih ^a   Kaymakoglu, Sabahattin ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; PEGINTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; VIRUS RNA;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DELTA AGENT HEPATITIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; MALE; NONHUMAN; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PREDICTION; PRIORITY JOURNAL; TREATMENT DURATION; VIRUS GENOME;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEPATITIS D, CHRONIC; HEPATITIS DELTA VIRUS; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MOLECULAR TYPING; POLYETHYLENE GLYCOLS; PROGNOSIS; RECOMBINANT PROTEINS; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84885348949     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2381     Document Type: Article

References (37)

1. Rizzetto M, Canese MG, Aricò S, et al. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut 1977; 18:997-1003.
2. Rizzetto M, Hoyer B, Purcell R, Gerin J. Hepatitis delta virus infection. In Vyas G, Dienstag J, Hoofnagle J (Editors). Viral hepatitis and liver disease. New York: Grune & Stratton 1984; pp. 371-377.
3. Rizzetto M, Verme G, Recchia S, et al. Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment. Ann Intern Med 1983; 98:437-441.
4. Saracco G, Rosina F, Brunetto MR, et al. Rapidly progressive HBsAg-positive hepatitis in Italy. The role of hepatitis delta virus infection. J Hepatol 1987; 5:274-281.
5. Farci P, Mandas A, Coiana A, et al. Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med 1994; 330:88-94.
6. Niro GA, Ciancio A, Tillman HL, et al. Lamivudine therapy in chronic delta hepatitis: a multicentre randomizedcontrolled pilot study. Aliment Pharmacol Ther 2005; 22:227-232.
7. Yurdaydin C, Wedemeyer H, Dalekos G, et al. A multicenter randomised study comparing the efficacy of pegylated interferon-alpha-2a plus adefovir dipivoxil vs. pegylated interferon-alpha-2a plus placebo vs. adefovir dipivoxil for the treatment of chronic delta hepatitis: the hep-net/international delta hepatitis intervention trial (HID-IT). Hepatology 2006; 44 Suppl 1:230A.
8. Yurdaydin C, Bozkaya H, Gürel S, et al. Famciclovir treatment of chronic delta hepatitis. J Hepatol 2002; 37:266-271.
9. Onder FO, Yakut M, Idilman R, et al. Entecavir may be beneficial in a subset of patients with chronic delta hepatitis. Hepatology 2009; 50 Suppl 4:735A.
10. Yurdaydin C, Bozkaya H, Onder FO, et al. Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon. J Viral Hepat 2008; 15:314-321.
11. Canbakan B, Senturk H, Tabak F, et al. Efficacy of interferon alpha-2b and lamivudine combination treatment in comparison to interferon alpha-2b alone in chronic delta hepatitis: a randomized trial. J Gastroenterol Hepatol 2006; 21:657-663.
12. Rasshofer R, Choi SS, Wolfl P, Roggendorf M. Interference of antiviral substances with replication of hepatitis delta virus RNA in primary woodchuck hepatocytes. Prog Clin Biol Res 1991; 364:223-234.
13. Kaymakoglu S, Karaca C, Demir K, et al. Alpha interferon and ribavirin combination therapy of chronic hepatitis D. Antimicrob Agents Chemother 2005; 49:1135-1138.
14. Gunsar F, Akarca US, Ersoz G, et al. Two-year interferon therapy with or without ribavirin in chronic delta hepatitis. Antivir Ther 2005; 10:721-726.
15. Erhardt A, Gerlich W, Starke C, et al. Treatment of chronic hepatitis delta with pegylated interferon-alpha2b. Liver Int 2006; 26:805-810.
16. Castelnau C, Le Gal F, Ripault MP, et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology 2006; 44:728-735.
17. Ormeci N, Bölükbas? F, Erden E, et al. Pegylated interferon alfa-2B for chronic delta hepatitis: 12 versus 24 months. Hepatogastroenterology 2011; 58:1648-1653.
18. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1:431-435.
19. Boom R, Sol CJ, Salimans MM, Jansen CL, Wertheim-van Dillen PM, van der Noordaa J. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990; 28:495-503.
20. Niro GA, Smedile A, Andriulli A, Rizzetto M, Gerin JL, Casey JL. The predominance of hepatitis delta virus genotype I among chronically infected Italian patients. Hepatology 1997; 25:728-734.
21. Ivaniushina V, Radjef N, Alexeeva M, et al. Hepatitis delta virus genotypes I and II cocirculate in an endemic area of Yakutia, Russia. J Gen Virol 2001; 82:2709-2718.
22. Rizzetto M. Hepatitis D: virology, clinical and epidemiological aspects. Acta Gastroenterol Belg 2000; 63:221-224.
23. Fattovich G, Boscaro S, Noventa F, et al. Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B. J Infect Dis 1987; 155:931-935.
24. Purcell RH, Rizzetto M, Gerin JL. Hepatitis delta virus infection of the liver. Semin Liver Dis 1984; 4:340-346.
25. Bahcecioglu IH, Aygun C, Gozel N, Poyrazoglu OK, Bulut Y, Yalniz M. Prevalence of hepatitis delta virus (HDV) infection in chronic hepatitis B patients in eastern Turkey: still a serious problem to consider. J Viral Hepat 2011; 18:518-524.
26. Rosina F, Conoscitore P, Cuppone R, et al. Changing pattern of chronic hepatitis D in southern Europe. Gastroenterology 1999; 117:161-166.
27. Uzunalimoglu O, Yurdaydin C, Cetinkaya H, et al. Risk factors for hepatocellular carcinoma in Turkey. Dig Dis Sci 2001; 46:1022-1028.
28. Degertekin H, Yalçin K, Yakut M, Yurdaydin C. Seropositivity for delta hepatitis in patients with chronic hepatitis B and liver cirrhosis in Turkey: a meta-analysis. Liver Int 2008; 28:494-498.
29. Berk L, de Man RA, Housset C, Berthelot P, Schalm SW. Alpha lymphoblastoid interferon and acyclovir for chronic hepatitis delta. Prog Clin Biol Res 1991; 364:411-420.
30. Wolters LM, van Nunen AB, Honkoop P, et al. Lamivudinehigh dose interferon combination therapy for chronic hepatitis B patients co-infected with the hepatitis D virus. J Viral Hepat 2000; 7:428-434.
31. Wedemeyer H, Yurdaydin C, Dalekos GN, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011; 364:322-331.
32. Garripoli A, Di Marco V, Cozzolongo R, et al. Ribavirin treatment for chronic hepatitis D: a pilot study. Liver 1994; 14:154-157.
33. Gaudin JL, Faure P, Godinot H, Gerard F, Trepo C. The French experience of treatment of chronic type D hepatitis with a 12-month course of interferon alpha-2B. Results of a randomized controlled trial. Liver 1995; 15:45-52.
34. Rosina F, Pintus C, Meschievitz C, Rizzetto M. A randomized controlled trial of a 12-month course of recombinant human interferon-alpha in chronic delta (type D) hepatitis: a multicenter Italian study. Hepatology 1991; 13:1052-1056.
35. Farci P, Roskams T, Chessa L, et al. Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology 2004; 126:1740-1749.
36. Triantos C, Kalafateli M, Nikolopoulou V, Burroughs A. Meta-analysis: antiviral treatment for hepatitis D. Aliment Pharmacol Ther 2012; 35:663-673.
37. Niro GA, Ciancio A, Gaeta GB, et al. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology 2006; 44:713-720.